BioXcel Therapeutics, Inc. Share Price

Equities

BTAI

US09075P1057

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 01/05/2024 BST 5-day change 1st Jan Change
2.54 USD +0.79% Intraday chart for BioXcel Therapeutics, Inc. -6.27% -13.90%
Sales 2024 * 3.45M 275M Sales 2025 * 9.13M 730M Capitalization 94.07M 7.51B
Net income 2024 * -97M -7.75B Net income 2025 * -83M -6.63B EV / Sales 2024 * 63.5 x
Net Debt 2024 * 125M 9.99B Net Debt 2025 * 115M 9.16B EV / Sales 2025 * 22.8 x
P/E ratio 2024 *
-0.91 x
P/E ratio 2025 *
-1.44 x
Employees 74
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.61%
More Fundamentals * Assessed data
Dynamic Chart
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment MT
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential CI
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants MT
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia MT
Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating MT
Transcript : BioXcel Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : Inflation Data -2- DJ
North American Morning Briefing : Nvidia Ignites -2- DJ
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9 MT
BioXcel Therapeutics Shares Soar After Terminating Proposed $60 Million Stock Offering MT
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer MT
BioXcel Therapeutics, Inc. Enter into the Third Amendment to Credit Agreement and Guaranty CI
More news
1 day+0.79%
1 week-6.27%
Current month+0.79%
1 month-9.93%
3 months-20.13%
6 months-42.14%
Current year-13.90%
More quotes
1 week
2.51
Extreme 2.51
2.70
1 month
2.51
Extreme 2.51
3.10
Current year
1.91
Extreme 1.91
4.17
1 year
1.91
Extreme 1.91
29.56
3 years
1.91
Extreme 1.91
39.00
5 years
1.91
Extreme 1.91
71.50
10 years
1.91
Extreme 1.91
71.50
More quotes
Managers TitleAgeSince
Founder 63 28/03/17
Director of Finance/CFO 66 30/09/17
Chief Tech/Sci/R&D Officer 68 31/05/17
Members of the board TitleAgeSince
Director/Board Member 67 30/06/22
Chairman 68 31/03/17
Director/Board Member 56 31/08/17
More insiders
Date Price Change Volume
01/05/24 2.54 +0.79% 210,560
30/04/24 2.52 -2.33% 164,938
29/04/24 2.58 -1.90% 339,321
26/04/24 2.63 +0.77% 260,297
25/04/24 2.61 -3.69% 665,832

Delayed Quote Nasdaq, May 01, 2024 at 09:00 pm

More quotes
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.54 USD
Average target price
7.25 USD
Spread / Average Target
+185.43%
Consensus